Clinical testing ProterixBio operates a CLIA-certified clinical testing laboratory with expertise in quantitative assays for inflammation and immune response, presenting a potential partner for contract testing, assay development, and clinical trial testing services.

Population health Focused on diagnostic solutions for population health and chronic care, especially vulnerable groups with COPD, diabetes, and cardiovascular disease, opening opportunities for co-development or commercialization partnerships in high-need segments.

Biomarker analytics Develops algorithms combining blood-based biomarkers to identify individuals at high risk for severe outcomes, suggesting collaboration opportunities in risk stratification tools, companion diagnostics, and data-driven health insights.

Recent COVID initiatives Past launches of serology and IgG antibody tests for COVID-19 with dried blood spot validation indicate readiness to expand remote or at-home sample collection partnerships and scalable assay deployment.

Scale and partnerships Revenue profile and substantial funding plus collaborations with academic medical centers imply a capacity for large-scale projects; target opportunities include co-development, manufacturing partnerships, and clinical trial support across mid-to-large biopharma and CROs.